JP2000514290A - 組換えアデノウイルスの製造方法 - Google Patents
組換えアデノウイルスの製造方法Info
- Publication number
- JP2000514290A JP2000514290A JP10503872A JP50387298A JP2000514290A JP 2000514290 A JP2000514290 A JP 2000514290A JP 10503872 A JP10503872 A JP 10503872A JP 50387298 A JP50387298 A JP 50387298A JP 2000514290 A JP2000514290 A JP 2000514290A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- adenovirus
- ultrafiltration
- cells
- supernatant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J41/00—Anion exchange; Use of material as anion exchangers; Treatment of material for improving the anion exchange properties
- B01J41/20—Anion exchangers for chromatographic processes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.パッケージング細胞培養物にウイルスDNAを導入し、産生したウイルスを 上清中に放出後に回収することを特徴とする組換えアデノウイルスの製造方法。 2.ウイルスの少なくとも50%が上清中に放出された時点で回収を行うことを 特徴とする請求項1に記載の方法。 3.ウイルスの少なくとも70%が上清中に放出された時点で回収を行うことを 特徴とする請求項1に記載の方法。 4.ウイルスの少なくとも90%が上清中に放出された時点で回収を行うことを 特徴とする請求項1に記載の方法。 5.限外濾過によりウイルスを回収することを特徴とする請求項1に記載の方法 。 6.限外濾過がタンジェント限外濾過であることを特徴とする請求項5に記載の 方法。 7.1000kDa未満のカットオフ閾値をもつ膜で限外濾過を行うことを特徴 とする請求項5又は6に記載の方法。 8.アニオン交換クロマトグラフィーによりウイルスを回収することを特徴とす る請求項1に記載の方法。 9.アニオン交換クロマトグラフィーが強アニオン交換クロマトグラフィーであ ることを特徴とする請求項8に記載の方法。 10.強アニオン交換クロマトグラフィーがSource Q、Mono Q、 Q Sepharose、Poros HQ及びPoros QE樹脂、Fra ctogel TMAE型樹脂及びToyopearl Super Qから選 択される支持体上で実施されることを特徴とする請求項9に記載の方法。 11.ゲル浸透クロマトグラフィーによりウイルスを回収することを特徴とする 請求項1に記載の方法。 12.ゲル浸透クロマトグラフィーがSephacryl S−500 HR、 Sephacryl S−1000 SF、Sephacryl S−1000 HR、Sephacryl S−2000、Superdex 200HR、 Sepharose 2B、4B又は6B及びTSK G6000 PWゲルか ら選択される支持体上で実施されることを特徴とする請求項11に記載の方法。 13.限外濾過後にアニオン交換クロマトグラフィーを実施することによりウイ ルスを回収することを特徴とする請求項1に記載の方法。 14.限外濾過後にアニオン交換クロマトグラフィーを実施し、更にその後、ゲ ル浸透クロマトグラフィーを実施することによりウイルスを回収することを特徴 とする請求項13に記載の方法。 15.パッケージング細胞がアデノウイルスのE1機能をトランス相補する細胞 であることを特徴とする請求項1から14のいずれか一項に記載の方法。 16.パッケージング細胞がアデノウイルスのE1及びE4機能をトランス相補 する細胞であることを特徴とする請求項15に記載の方法。 17.パッケージング細胞がアデノウイルスのE1及びE2a機能をトランス相 補する細胞であることを特徴とする請求項15に記載の方法。 18.細胞がヒト胎児腎細胞、ヒト網膜芽細胞又はヒト肺癌細胞であることを特 徴とする請求項15から17のいずれか一項に記載の方法。 19.強アニオン交換クロマトグラフィーによる精製段階を含むことを特徴とす る生物培地からの組換えアデノウイルスの精製方法。 20.生物培地が前記ウイルスを産生するパッケージング細胞の上清であること を特徴とする請求項19に記載の方法。 21.生物培地が前記ウイルスを産生するパッケージング細胞の溶解液であるこ とを特徴とする請求項19に記載の方法。 22.生物培地が前記ウイルスから予備精製された溶液であることを特徴とする 請求項19に記載の方法。 23.第4級アミンで官能化した支持体上でクロマトグラフィーを行うことを特 徴とする請求項19に記載の方法。 24.支持体がアガロース、デキストラン、アクリルアミド、シリカ、ポリ[ス チレン−ジビニルベンゼン]、エチレングリコール−メタクリレートコポリマー から単独又は混合物として選択されることを特徴とする請求項23に記載の方法 。 25.クロマトグラフィーがSource Q、Mono Q、Q Sepha rose、Poros HQ、Poros QE、Fractogel TMA E又はToyopearl Super Q樹脂上で実施されることを特徴とす る請求項24に記載の方法。 26.クロマトグラフィーがSource Q、好ましくはSource Q1 5樹脂上で実施されることを特徴とする請求 項25に記載の方法。 27.予備限外濾過段階を含むことを特徴とする請求項19に記載の方法。 28.限外濾過が300〜500kDaのカットオフ閾値をもつ膜によるタンジ ェント限外濾過であることを特徴とする請求項27に記載の方法。 29.請求項1又は19に記載の方法により得られる精製ウイルス調製物。 30.請求項29に記載のウイルス調製物と、医薬的に許容可能なベクターを含 む医薬組成物。 31.アデノウイルスの精製のためのヨージキサノール−5,5’−[(2−ヒ ドロキシ−1,3−プロパンジイル)ビス(アセチルアミノ)]ビス[N,N’ −ビス−(2,3−ジヒドロキシプロピル−2,4,6−トリヨード−1,3− ベンゼンカルボキサミド)]の使用。 32.第1の超遠心段階と、第2の希釈又は透析段階と、第3のアニオン交換ク ロマトグラフィー段階を含む、生物培地からのアデノウイルスの精製方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9608164A FR2750433B1 (fr) | 1996-07-01 | 1996-07-01 | Procede de production d'adenovirus recombinants |
US2666796P | 1996-09-25 | 1996-09-25 | |
US60/026,667 | 1996-09-25 | ||
US96/08164 | 1996-09-25 | ||
PCT/FR1997/001107 WO1998000524A1 (fr) | 1996-07-01 | 1997-06-20 | Procede de production d'adenovirus recombinants |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000514290A true JP2000514290A (ja) | 2000-10-31 |
Family
ID=26232805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP10503872A Ceased JP2000514290A (ja) | 1996-07-01 | 1997-06-20 | 組換えアデノウイルスの製造方法 |
Country Status (13)
Country | Link |
---|---|
US (3) | US6485958B2 (ja) |
EP (1) | EP0944717A1 (ja) |
JP (1) | JP2000514290A (ja) |
KR (1) | KR20050043996A (ja) |
AU (1) | AU3447097A (ja) |
BR (1) | BR9710030A (ja) |
CA (1) | CA2258158A1 (ja) |
CZ (1) | CZ438398A3 (ja) |
HU (1) | HU224558B1 (ja) |
IL (1) | IL127692A0 (ja) |
NO (1) | NO986202L (ja) |
SK (1) | SK181098A3 (ja) |
WO (1) | WO1998000524A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015126757A (ja) * | 2010-04-14 | 2015-07-09 | イーエムディー・ミリポア・コーポレーションEMD Millipore Corporation | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
JP2016509836A (ja) * | 2013-02-28 | 2016-04-04 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
JP2017522047A (ja) * | 2014-06-27 | 2017-08-10 | アンジオクライン・バイオサイエンス・インコーポレイテッドAngiocrine Bioscience, Inc. | アデノウイルスe4qrf1を発現する神経系細胞、並びに、その製造および使用方法 |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11511326A (ja) * | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
AU3447097A (en) * | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
ATE348155T1 (de) | 1996-11-20 | 2007-01-15 | Introgen Therapeutics Inc | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
US20080261289A1 (en) * | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
US6544769B1 (en) * | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
CA2274876A1 (en) | 1996-12-13 | 1998-06-18 | Schering Corporation | Method for purifying viruses |
US6146891A (en) | 1997-01-31 | 2000-11-14 | Schering Corporation | Methods for cultivating cells and propagating viruses |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6989264B2 (en) * | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
PL343630A1 (en) | 1998-04-22 | 2001-08-27 | Genvec Inc | Efficient purification of adenovirus |
AU770672B2 (en) * | 1998-05-27 | 2004-02-26 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient |
EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
PL349074A1 (en) * | 1998-12-31 | 2002-07-01 | Aventis Pharma Sa | Method for separating viral particles |
FR2788064B1 (fr) * | 1998-12-31 | 2003-01-31 | Aventis Pharma Sa | Methode de separation de particules virales |
DE60029195T2 (de) | 1999-02-22 | 2007-06-28 | Transgene S.A. | Verfahren zur Gewinnung von purifizierter Virenzusammensetzung |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
EP1427835B1 (en) * | 2001-08-08 | 2016-01-20 | The Trustees of the University of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
DE60233061D1 (de) * | 2001-09-06 | 2009-09-03 | Alphavax Inc | Alphavirus replikon-vektorsysteme |
EP1453537A1 (en) | 2001-12-12 | 2004-09-08 | FH Faulding & Co. Limited | Composition for viral preservation |
JP2005515245A (ja) * | 2002-01-18 | 2005-05-26 | シエーリング アクチエンゲゼルシャフト | アデノウィルスの安定化された配合物 |
US20030224354A1 (en) * | 2002-05-30 | 2003-12-04 | Introgen Therapeutics Inc. | Quantifying viral particles with intrinsic fluorescence |
EP1371723A1 (en) * | 2002-06-12 | 2003-12-17 | Procorde GmbH | Process for preparing an adenovirus-containing preparation |
CA2496918A1 (en) * | 2002-08-28 | 2004-03-11 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
BRPI0317276B8 (pt) * | 2002-12-13 | 2021-05-25 | Alphavax Inc | método para a preparação de partículas de replicon de alfavírus (arps) |
EP1585812B1 (en) * | 2002-12-13 | 2017-01-18 | Alphavax, Inc. | Multi-antigenic alphavirus replicon particles and methods |
KR101454842B1 (ko) * | 2003-03-20 | 2014-11-04 | 알파벡스, 인크. | 개선된 알파바이러스 레플리콘 및 헬퍼 구축물 |
US20040229335A1 (en) | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
EP1633321A4 (en) * | 2003-06-18 | 2006-11-02 | Onyx Pharma Inc | METHOD FOR CLEANING VIRUS |
PT1651666E (pt) * | 2003-07-11 | 2009-08-28 | Alphavax Inc | Vacinas de citomegalovírus à base de alfavírus |
DE602004031681D1 (de) | 2003-07-21 | 2011-04-14 | Transgene Sa | Multifunktionelle Cytokine |
NZ548495A (en) * | 2004-02-23 | 2009-05-31 | Crucell Holland Bv | Virus purification methods |
JP5065024B2 (ja) | 2004-05-18 | 2012-10-31 | アルファバックス,インコーポレイティド | Tc−83由来アルファウイルスベクター、粒子および方法 |
AU2005305347A1 (en) | 2004-11-03 | 2006-05-18 | Introgen Therapeutics Inc. | Method of producing and purifying of adenoviral vectors |
WO2006057876A2 (en) * | 2004-11-22 | 2006-06-01 | Cedars-Sinai Medical Center | Methods and solutions for tissue preservation |
KR101447897B1 (ko) | 2005-03-21 | 2014-10-07 | 비로베이, 인코포레이티드 | 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물 |
ATE412737T1 (de) * | 2005-04-11 | 2008-11-15 | Crucell Holland Bv | Virusreinigung mit ultrafiltration |
WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
ATE518958T1 (de) | 2007-01-30 | 2011-08-15 | Transgene Sa | Zur impfung verwendetes papillomavirus-e2- polypeptid |
PL2947149T3 (pl) | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
EA019928B1 (ru) * | 2008-11-03 | 2014-07-30 | Круселл Холланд Б.В. | Способ получения аденовирусных векторов |
TWI555531B (zh) | 2009-08-07 | 2016-11-01 | 傳斯堅公司 | 用以治療b型肝炎病毒(hbv)感染之組成物 |
ES2472429T3 (es) | 2009-10-15 | 2014-07-01 | Crucell Holland B.V. | Método para la purificación de partículas de adenovirus a partir de cultivos de alta densidad celular |
ES2445713T3 (es) | 2009-10-15 | 2014-03-04 | Crucell Holland B.V. | Proceso para la purificación de adenovirus a partir de cultivos de alta densidad celular |
BR112012019023B1 (pt) | 2010-02-15 | 2021-12-21 | Janssen Vaccines & Prevention B.V. | Método para produzir adenovírus recombinante sorotipo 26 (rad26), e, uso de um biorreator |
EP2649178B8 (en) | 2010-12-09 | 2017-08-30 | Institut Pasteur | Mgmt-based method for obtaining high yield of recombinant protein expression |
TWI623618B (zh) | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
WO2013045668A2 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
CA2864956C (en) | 2012-03-12 | 2021-11-09 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
AU2013237429B2 (en) | 2012-03-22 | 2015-07-23 | Crucell Holland B.V. | Vaccine against RSV |
CA2875683A1 (en) | 2012-06-05 | 2013-12-12 | The Australian National University | Vaccination with interleukin-4 antagonists |
JP6430949B2 (ja) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Gm−csfとil−4のコンジュゲート、組成物、ならびにそれに関連する方法 |
AU2014236207B2 (en) | 2013-03-14 | 2019-05-23 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
EA035522B1 (ru) | 2013-04-25 | 2020-06-29 | Янссен Вэксинс Энд Превеншн Б.В. | Стабильные растворимые f-полипептиды rsv в конформации "до слияния" |
CA2914792C (en) | 2013-06-17 | 2024-02-27 | Crucell Holland B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
GB201415579D0 (en) * | 2014-09-03 | 2014-10-15 | Psioxus Therapeutics Ltd | A process |
SG11201701502VA (en) * | 2014-08-27 | 2017-03-30 | Psioxus Therapeutics Ltd | A process for the production of adenovirus |
SG11201704919SA (en) | 2015-01-13 | 2017-07-28 | Alfa Wassermann Inc | Methods of purifying adeno-associated virus (aav) and/or recombinant adeno-associated virus (raav) |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
CA2981841A1 (en) | 2015-04-14 | 2016-10-20 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
IL288541B (en) | 2015-07-07 | 2022-08-01 | Janssen Vaccines Prevention B V | vaccine against rsv |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
SG11201807913XA (en) | 2016-04-05 | 2018-10-30 | Janssen Vaccines & Prevention Bv | Stabilized soluble pre-fusion rsv f proteins |
JP7233928B2 (ja) | 2016-04-05 | 2023-03-07 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Rsvに対するワクチン |
WO2017191147A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
RU2758238C2 (ru) | 2016-05-12 | 2021-10-26 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
IL264119B2 (en) | 2016-05-30 | 2023-04-01 | Janssen Vaccines Prevention B V | f proteins of rsv are stabilized before fusion |
RU2745500C2 (ru) | 2016-06-20 | 2021-03-25 | Янссен Вэксинс Энд Превеншн Б.В. | Эффективный и сбалансированный двунаправленный промотор |
JP7229151B2 (ja) | 2016-07-14 | 2023-02-27 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Hpvワクチン |
WO2018069316A2 (en) | 2016-10-10 | 2018-04-19 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
CA3044074A1 (en) | 2016-11-16 | 2018-05-24 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
EP3532082A4 (en) | 2016-12-12 | 2020-08-26 | Salk Institute for Biological Studies | SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES |
KR102111244B1 (ko) | 2017-02-09 | 2020-05-15 | 얀센 백신스 앤드 프리벤션 비.브이. | 이종 유전자의 발현을 위한 강력한 짧은 프로모터 |
BR112019022108A2 (pt) | 2017-04-22 | 2020-05-12 | Immunomic Therapeutics, Inc. | Construções de lamp aprimoradas |
CN110913892A (zh) | 2017-05-02 | 2020-03-24 | 免疫治疗有限公司 | 包含癌抗原的lamp(溶酶体相关膜蛋白)构建物 |
AU2018267971A1 (en) | 2017-05-17 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
US11229695B2 (en) | 2017-09-15 | 2022-01-25 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against RSV |
CA3100004A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc. | Improved lamp constructs comprising allergens |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
EP3927833A4 (en) | 2019-02-21 | 2022-11-30 | Unleash Immuno Oncolytics, Inc. | ONCOLYTIC ADENOVIRAL VECTOR AND METHODS OF USE |
US20240108703A1 (en) | 2019-10-18 | 2024-04-04 | Immunomic Therapeutics, Inc. | Improved LAMP Constructs Comprising Cancer Antigens |
BR112022009598A2 (pt) | 2019-11-18 | 2022-08-16 | Janssen Biotech Inc | Vacinas baseadas em calr e jak2 mutantes e uso dos mesmos |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
US20210315986A1 (en) | 2020-04-13 | 2021-10-14 | Janssen Biotech, Inc. | Psma and steap1 vaccines and their uses |
US20230029453A1 (en) | 2020-07-06 | 2023-02-02 | Janssen Biotech, Inc. | Prostate Neoantigens And Their Uses |
EP4175721A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
EP4176087A1 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
JPH09508017A (ja) * | 1994-01-12 | 1997-08-19 | ジェネティック セラピー,インコーポレイテッド | レトロウイルスベクターの精製 |
FR2716893B1 (fr) | 1994-03-03 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, leur préparation et leur utilisation thérapeutique. |
WO1995025789A1 (en) | 1994-03-22 | 1995-09-28 | The Immune Response Corporation | Highly efficient production and isolation of viral particles |
US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
AU3447097A (en) * | 1996-07-01 | 1998-01-21 | Rhone-Poulenc Rorer S.A. | Method for producing recombinant adenovirus |
ATE348155T1 (de) | 1996-11-20 | 2007-01-15 | Introgen Therapeutics Inc | Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren |
US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
PL349074A1 (en) * | 1998-12-31 | 2002-07-01 | Aventis Pharma Sa | Method for separating viral particles |
-
1997
- 1997-06-20 AU AU34470/97A patent/AU3447097A/en not_active Abandoned
- 1997-06-20 EP EP97930560A patent/EP0944717A1/fr not_active Ceased
- 1997-06-20 SK SK1810-98A patent/SK181098A3/sk unknown
- 1997-06-20 CA CA002258158A patent/CA2258158A1/fr not_active Abandoned
- 1997-06-20 KR KR1020057007148A patent/KR20050043996A/ko active IP Right Grant
- 1997-06-20 BR BR9710030A patent/BR9710030A/pt not_active Application Discontinuation
- 1997-06-20 IL IL12769297A patent/IL127692A0/xx unknown
- 1997-06-20 CZ CZ984383A patent/CZ438398A3/cs unknown
- 1997-06-20 HU HU0001271A patent/HU224558B1/hu not_active IP Right Cessation
- 1997-06-20 WO PCT/FR1997/001107 patent/WO1998000524A1/fr not_active Application Discontinuation
- 1997-06-20 JP JP10503872A patent/JP2000514290A/ja not_active Ceased
- 1997-06-20 US US09/202,545 patent/US6485958B2/en not_active Expired - Fee Related
-
1998
- 1998-12-30 NO NO986202A patent/NO986202L/no not_active Application Discontinuation
-
2002
- 2002-10-10 US US10/267,865 patent/US6905862B2/en not_active Expired - Fee Related
-
2005
- 2005-03-23 US US11/086,678 patent/US20050287657A1/en not_active Abandoned
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015126757A (ja) * | 2010-04-14 | 2015-07-09 | イーエムディー・ミリポア・コーポレーションEMD Millipore Corporation | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
US9644187B2 (en) | 2010-04-14 | 2017-05-09 | Emd Millipore Corporation | Methods of producing high titer, high purity virus stocks and methods of use thereof |
JP2017195897A (ja) * | 2010-04-14 | 2017-11-02 | イーエムディー・ミリポア・コーポレーションEMD Millipore Corporation | 高力価、高純度のウイルスストックの作製方法及びその使用方法 |
JP2016509836A (ja) * | 2013-02-28 | 2016-04-04 | サイオクサス セラピューティクス リミテッド | アデノウイルスの製造方法 |
JP2017522047A (ja) * | 2014-06-27 | 2017-08-10 | アンジオクライン・バイオサイエンス・インコーポレイテッドAngiocrine Bioscience, Inc. | アデノウイルスe4qrf1を発現する神経系細胞、並びに、その製造および使用方法 |
Also Published As
Publication number | Publication date |
---|---|
NO986202D0 (no) | 1998-12-30 |
CZ438398A3 (cs) | 1999-03-17 |
HU224558B1 (hu) | 2005-10-28 |
BR9710030A (pt) | 1999-08-10 |
US6905862B2 (en) | 2005-06-14 |
KR20050043996A (ko) | 2005-05-11 |
HUP0001271A3 (en) | 2002-01-28 |
HUP0001271A1 (hu) | 2000-08-28 |
IL127692A0 (en) | 1999-10-28 |
US20020028497A1 (en) | 2002-03-07 |
US6485958B2 (en) | 2002-11-26 |
AU3447097A (en) | 1998-01-21 |
NO986202L (no) | 1999-02-15 |
SK181098A3 (en) | 1999-07-12 |
CA2258158A1 (fr) | 1998-01-08 |
WO1998000524A1 (fr) | 1998-01-08 |
US20030143730A1 (en) | 2003-07-31 |
EP0944717A1 (fr) | 1999-09-29 |
US20050287657A1 (en) | 2005-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2000514290A (ja) | 組換えアデノウイルスの製造方法 | |
WO1998000524A9 (fr) | Procede de production d'adenovirus recombinants | |
KR100762033B1 (ko) | 바이러스 입자의 분리방법 | |
RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
JP6009357B2 (ja) | アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物 | |
US20080194002A1 (en) | Compositions comprising viruses and methods for concentrating virus preparations | |
EP1054955A2 (en) | Compositions comprising viruses and methods for concentrating virus preparations | |
Sviben et al. | Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio | |
Segura et al. | Chromatography purification of canine adenoviral vectors | |
Ugai et al. | Thermostability/infectivity defect caused by deletion of the core protein V gene in human adenovirus type 5 is rescued by thermo-selectable mutations in the core protein X precursor | |
JPH10506018A (ja) | 不活化IVa2遺伝子を有する欠陥組換えアデノウィルス | |
Pogo et al. | Investigation of vaccinia virus DNA replication employing a conditional lethal mutant defective in DNA | |
KR100514589B1 (ko) | 재조합아데노바이러스의제조방법 | |
FR2750433A1 (fr) | Procede de production d'adenovirus recombinants | |
AU778287B2 (en) | Method for producing recombinant adenovirus | |
AU2004201075B2 (en) | Method for producing recombinant adenovirus | |
MXPA99000230A (en) | Procedure of production of adenovirus recombinan | |
Rajagopalan et al. | Viable variants in VA-RNAI gene of an Ad2-Ad5 recombinant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040401 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050304 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070423 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070725 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080115 |